Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly
- Conditions
- HypoxiaExerciseCerebral HypoxiaBrain DiseasesAgingCognitive DeclineHealthy Aging
- Registration Number
- NCT05048680
- Lead Sponsor
- University Hospital, Grenoble
- Brief Summary
In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 64
- 60 to 80 years of age;
- Being physically inactive (less than 150 min/week of moderate to intense physical activity);
- No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;
- Health coverage;
- Being able to provide written fully informed consent.
- Body-mass index >30 kg/m2;
- Smoking (> cigarettes/day);
- Alcohol use (> 10g/day);
- Mental disorder or history of mental disorder;
- Beta-blockade treatment;
- Inability or refusal to provide informed consent;
- No health coverage
- People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;
- People deprived of freedom by judicial or administrative decision;
- People subject to legal protection, who cannot be included in clinical trials.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Middle cerebral artery flow velocity Before intervention; right after intervention; 2 months after intervention Changes in middle cerebral artery flow velocity in response to hypercapnia (5% CO2)
- Secondary Outcome Measures
Name Time Method Cognitive function Before intervention; right after intervention; 2 months after intervention Cognitive function assessed by the Montreal Cognitive Assessment questionnaire
Health-related quality of life Before intervention; right after intervention; 2 months after intervention Health-related quality of life assessed by the SF-36 questionnaire
Blood pressure Before intervention; right after intervention; 2 months after intervention 24h (systolic, diastolic and mean) blood pressure assessment
Sleep Before intervention; right after intervention; 2 months after intervention Sleep features assessed by polygraphy
Peak oxygen uptake Before intervention; right after intervention; 2 months after intervention Peak oxygen uptake during a cardiopulmonary exercise test
Flow-mediated dilation Before intervention; right after intervention; 2 months after intervention Flow-mediated dilation in response to ischemia-reperfusion of the brachial artery
Trial Locations
- Locations (1)
CHU Grenoble Alpes
🇫🇷La Tronche, Auvergne Rhône-Alpes, France
CHU Grenoble Alpes🇫🇷La Tronche, Auvergne Rhône-Alpes, FranceStéphane Doutreleau, MD, PhDContact+33476767773sdoutreleau@chu-grenoble.frSamuel Vergès, PhDContact+33476766860sverges@chu-grenoble.fr